Clinical Trials Logo

Clinical Trial Summary

This study is a multicenter, single-arm, open-label Phase II clinical trial evaluating TK216 in combination with vincristine in the treatment of relapsed or refractory Ewing sarcoma (ES) including Ewing's sarcoma family tumors (ESFTs).


Clinical Trial Description

Ewing sarcoma is characterized by genomic rearrangements resulting in over-expression of ets family transcription factors driving tumor progression. TK216 is designed to inhibit this effect by inhibiting downstream effects of the EWS-FLI1 transcription factor. Based on USA RP2D result, designed as a single arm, multicenter open-label study,this study is the first study of TK216 in Chinese subjects with Ewing sarcoma. The study is designed to establish safety and efficacy data in combination with vincristine to assess the potential of TK216 for further development. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05046314
Study type Interventional
Source Shanghai Pharmaceuticals Holding Co., Ltd
Contact Yang Yao
Phone 13916138801
Email yangyao_6@hotmail.com
Status Recruiting
Phase Phase 2
Start date March 12, 2024
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05440786 - CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma Phase 2
Completed NCT01661400 - Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors Phase 1
Completed NCT03275818 - Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma Phase 2
Recruiting NCT06387485 - A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning N/A
Active, not recruiting NCT02415816 - Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas N/A
Not yet recruiting NCT04890093 - Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03778996 - SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma Phase 2
Terminated NCT02581384 - Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors Phase 1/Phase 2
Enrolling by invitation NCT05772312 - Quality of Life of Patients With Bone Tumor of the Lower Limbs Treated With Salvage Surgery
Withdrawn NCT02557854 - HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors Phase 1
Terminated NCT03495921 - A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide Phase 3
Terminated NCT02657005 - TK216 in Patients With Relapsed or Refractory Ewing Sarcoma Phase 1/Phase 2
Completed NCT05100368 - The Prognostic Value of Serum Biomarkers in Ewing's Sarcoma